CML: What to Do When Frontline Tyrosine Kinase Inhibitor Therapy Has Failed

This protocol covers the clinical scenario in which a patient with chronic myeloid leukemia has received frontline tyrosine kinase inhibitor (TKI) therapy but has not achieved the required cytogenetic or molecular response milestones. A defined next-line approach is indicated in this setting.

Previous Line — Failure Condition

Frontline TKI therapy with imatinib, dasatinib, nilotinib, or bosutinib did not achieve early molecular response (BCR::ABL1 transcripts <10% at 3 or 6 months), complete cytogenetic response (BCR::ABL1 ≤1%) at 12 months, or major molecular response (BCR::ABL1 ≤0.1%). This failure to reach response milestones is the trigger for escalation to this protocol.

Next-Line Treatment Approach (Partial Preview)

The strategy involves switching to a second-generation tyrosine kinase inhibitor, with agent selection informed in part by the patient's mutation profile. The complete selection criteria, sequencing, and decision algorithm are available in the full protocol.

Treatment Goals

Complete cytogenetic response (CCyR; BCR::ABL1 transcripts [IS] ≤1%) and major molecular response (MMR).

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/ajh.27443

Based on these studies, several noteworthy ideas have emerged.
First, second-line treatment with dasatinib, bosutinib, or nilotinib can yield high rates of responses in patients who have inadequate response to imatinib, including high rates of MMR, and they are better than imatinib dose escalation.
Physician may favor dasatinib or bosutinib if the patient has the following mutations: Y253H, E255K/V, or F359C/V.
Alternatively, nilotinib may be favored in the presence of the V299L and F317L mutations.

View source ↗